During the past 12 months, Protalix BioTherapeutics's average Total Assets Growth Rate was 18.60% per year.
During the past 3 years, the average Total Assets Growth Rate was 10.70% per year.
During the past 5 years, the average Total Assets Growth Rate was 10.30% per year.
During the past 10 years, the average Total Assets Growth Rate was 5.70% per year.
During the past 13 years, Protalix BioTherapeutics's highest 3-Year average Total Assets Growth Rate was 1367.80%. The lowest was -81.10%. And the median was 6.80%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Protalix BioTherapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protalix BioTherapeutics (AMEX:PLX) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Protalix BioTherapeutics's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Protalix BioTherapeutics Total Assets Related Terms
Thank you for viewing the detailed overview of Protalix BioTherapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Protalix BioTherapeutics (Protalix BioTherapeutics) Business Description
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substance to Pfizer under its Amended Pfizer Agreement.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PLX has been successfully added to your 